Fine‐tuning of frontline tyrosine kinase inhibitor (TKI) therapy in chronic‐phase chronic myeloid leukemia: The choice of the right TKI for the right patient 🔗 Access full article via ACS Cancer Cancer, EarlyView.com Share:TwitterFacebookEmailRedditMoreLinkedInWhatsAppTelegramMastodon
